Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 59009 | 5.2 |
09:34 ET | 9066 | 5.22 |
09:36 ET | 1509 | 5.1597 |
09:38 ET | 4721 | 5.25 |
09:39 ET | 1410 | 5.2825 |
09:41 ET | 1953 | 5.26 |
09:43 ET | 10334 | 5.3 |
09:45 ET | 1746 | 5.2 |
09:48 ET | 1675 | 5.22 |
09:50 ET | 2417 | 5.245 |
09:52 ET | 1276 | 5.21 |
09:54 ET | 2627 | 5.17 |
09:56 ET | 1035 | 5.1215 |
09:57 ET | 1802 | 5.15 |
09:59 ET | 1262 | 5.13 |
10:01 ET | 532 | 5.135 |
10:03 ET | 705 | 5.15 |
10:06 ET | 1100 | 5.155 |
10:08 ET | 780 | 5.17 |
10:10 ET | 531 | 5.175 |
10:12 ET | 166 | 5.17 |
10:14 ET | 20423 | 5.0905 |
10:15 ET | 4332 | 5.08 |
10:17 ET | 3584 | 5.1327 |
10:19 ET | 873 | 5.145 |
10:21 ET | 400 | 5.16 |
10:24 ET | 1977 | 5.15 |
10:26 ET | 858 | 5.17 |
10:28 ET | 766 | 5.21 |
10:30 ET | 1050 | 5.21 |
10:32 ET | 800 | 5.21 |
10:33 ET | 2350 | 5.23 |
10:35 ET | 300 | 5.24 |
10:37 ET | 3052 | 5.239 |
10:39 ET | 694 | 5.26 |
10:42 ET | 5355 | 5.22 |
10:44 ET | 2149 | 5.26 |
10:46 ET | 11525 | 5.32 |
10:48 ET | 3185 | 5.275 |
10:50 ET | 800 | 5.29 |
10:51 ET | 600 | 5.2601 |
10:53 ET | 4899 | 5.29 |
10:55 ET | 1018 | 5.29 |
10:57 ET | 100 | 5.28 |
11:00 ET | 2881 | 5.285 |
11:02 ET | 8476 | 5.28 |
11:04 ET | 200 | 5.28 |
11:06 ET | 1100 | 5.2795 |
11:08 ET | 1100 | 5.28 |
11:09 ET | 1933 | 5.27 |
11:11 ET | 1263 | 5.28 |
11:13 ET | 1573 | 5.28 |
11:18 ET | 2985 | 5.315 |
11:20 ET | 5788 | 5.32 |
11:22 ET | 7111 | 5.33 |
11:24 ET | 9473 | 5.301 |
11:26 ET | 18922 | 5.378 |
11:27 ET | 3186 | 5.3693 |
11:29 ET | 1252 | 5.35 |
11:31 ET | 2994 | 5.38 |
11:33 ET | 3076 | 5.41 |
11:36 ET | 2779 | 5.4 |
11:38 ET | 3580 | 5.405 |
11:40 ET | 2219 | 5.41 |
11:42 ET | 1600 | 5.4 |
11:44 ET | 4437 | 5.36 |
11:45 ET | 3450 | 5.36 |
11:47 ET | 821 | 5.37 |
11:49 ET | 1616 | 5.39 |
11:51 ET | 941 | 5.42 |
11:54 ET | 1905 | 5.41 |
11:56 ET | 3623 | 5.4 |
11:58 ET | 1800 | 5.39 |
12:00 ET | 1200 | 5.39 |
12:02 ET | 200 | 5.4 |
12:03 ET | 700 | 5.41 |
12:05 ET | 200 | 5.41 |
12:07 ET | 2150 | 5.4 |
12:09 ET | 3778 | 5.395 |
12:12 ET | 3022 | 5.365 |
12:14 ET | 2674 | 5.34 |
12:16 ET | 2066 | 5.34 |
12:18 ET | 2446 | 5.31 |
12:20 ET | 379 | 5.32 |
12:21 ET | 713 | 5.33 |
12:23 ET | 6300 | 5.34 |
12:25 ET | 2294 | 5.35 |
12:27 ET | 700 | 5.34 |
12:30 ET | 5485 | 5.309 |
12:32 ET | 400 | 5.31 |
12:34 ET | 2161 | 5.33 |
12:36 ET | 650 | 5.35 |
12:38 ET | 837 | 5.37 |
12:39 ET | 639 | 5.38 |
12:41 ET | 624 | 5.4 |
12:43 ET | 3666 | 5.38 |
12:45 ET | 300 | 5.38 |
12:48 ET | 3135 | 5.39 |
12:50 ET | 2613 | 5.35 |
12:52 ET | 2578 | 5.365 |
12:54 ET | 712 | 5.37 |
12:56 ET | 200 | 5.379 |
12:57 ET | 1704 | 5.37 |
12:59 ET | 1818 | 5.39 |
01:01 ET | 1556 | 5.39 |
01:03 ET | 600 | 5.4 |
01:06 ET | 1160 | 5.41 |
01:08 ET | 17669 | 5.45 |
01:10 ET | 1641 | 5.45 |
01:12 ET | 1200 | 5.47 |
01:14 ET | 100 | 5.47 |
01:15 ET | 3969 | 5.44 |
01:17 ET | 728 | 5.44 |
01:19 ET | 3183 | 5.44 |
01:21 ET | 12041 | 5.48 |
01:24 ET | 300 | 5.48 |
01:26 ET | 100 | 5.48 |
01:28 ET | 2751 | 5.4728 |
01:30 ET | 3668 | 5.49 |
01:32 ET | 2730 | 5.48 |
01:33 ET | 1617 | 5.49 |
01:35 ET | 3536 | 5.49 |
01:37 ET | 1977 | 5.49 |
01:39 ET | 7595 | 5.46 |
01:42 ET | 2419 | 5.45 |
01:44 ET | 2100 | 5.4597 |
01:46 ET | 2656 | 5.46 |
01:48 ET | 1537 | 5.46 |
01:50 ET | 8294 | 5.44 |
01:51 ET | 1000 | 5.44 |
01:53 ET | 208 | 5.44 |
01:55 ET | 1217 | 5.44 |
01:57 ET | 600 | 5.45 |
02:00 ET | 19255 | 5.46 |
02:02 ET | 708 | 5.46 |
02:04 ET | 100 | 5.47 |
02:06 ET | 4000 | 5.44 |
02:08 ET | 1432 | 5.42 |
02:09 ET | 800 | 5.43 |
02:11 ET | 4182 | 5.45 |
02:13 ET | 700 | 5.46 |
02:15 ET | 812 | 5.46 |
02:18 ET | 1000 | 5.47 |
02:20 ET | 3588 | 5.43 |
02:22 ET | 4296 | 5.47 |
02:24 ET | 8724 | 5.461 |
02:26 ET | 719 | 5.48 |
02:27 ET | 100 | 5.47 |
02:29 ET | 2101 | 5.45 |
02:31 ET | 8993 | 5.42 |
02:33 ET | 4941 | 5.42 |
02:36 ET | 9085 | 5.43 |
02:38 ET | 5534 | 5.4 |
02:40 ET | 800 | 5.39 |
02:42 ET | 14824 | 5.36 |
02:44 ET | 14874 | 5.33 |
02:45 ET | 3100 | 5.36 |
02:47 ET | 1100 | 5.35 |
02:49 ET | 9402 | 5.37 |
02:51 ET | 3302 | 5.37 |
02:54 ET | 2200 | 5.38 |
02:56 ET | 1300 | 5.37 |
02:58 ET | 2818 | 5.375 |
03:00 ET | 2834 | 5.37 |
03:02 ET | 9721 | 5.33 |
03:03 ET | 5602 | 5.36 |
03:05 ET | 10256 | 5.36 |
03:07 ET | 411 | 5.36 |
03:09 ET | 4564 | 5.32 |
03:12 ET | 2254 | 5.31 |
03:14 ET | 4106 | 5.3 |
03:16 ET | 2300 | 5.31 |
03:18 ET | 3779 | 5.31 |
03:20 ET | 3291 | 5.32 |
03:21 ET | 4514 | 5.29 |
03:23 ET | 6098 | 5.29 |
03:25 ET | 1900 | 5.26 |
03:27 ET | 7759 | 5.28 |
03:30 ET | 7547 | 5.29 |
03:32 ET | 14494 | 5.21 |
03:34 ET | 23193 | 5.14 |
03:36 ET | 27176 | 5.12 |
03:38 ET | 10114 | 5.09 |
03:39 ET | 20498 | 5.14 |
03:41 ET | 30568 | 5.1199 |
03:43 ET | 17288 | 5.115 |
03:45 ET | 23126 | 5.12 |
03:48 ET | 12814 | 5.12 |
03:50 ET | 35660 | 5.23 |
03:52 ET | 59030 | 5.13 |
03:54 ET | 26584 | 5.19 |
03:56 ET | 64830 | 5.25 |
03:57 ET | 23249 | 5.23 |
03:59 ET | 5253635 | 5.26 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 189.1M | -1.5x | --- |
Trevi Therapeutics Inc | 190.2M | -8.0x | --- |
Design Therapeutics Inc | 191.0M | -3.2x | --- |
Candel Therapeutics Inc | 179.7M | -4.7x | --- |
Pyxis Oncology Inc | 198.5M | -2.4x | --- |
Outlook Therapeutics Inc | 178.6M | -0.7x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $189.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.